BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease: its role in remission induction and maintenance.
BCNU is an effective antitumor agent in the treatment of Hodgkin's disease. Forty-seven percent of a group of patients with advanced disease, refractory to combination or sequential-agent chemotherapy, achieved an objective response to BCNU. Bone marrow toxicity was delayed in onset and was dose related. When incorporated into a maintenance program after remission induction with combination chemotherapy, BCNU appeared to delay, but not ultimately prevent, relapses during a 2-year followup period. Toxic effects associated with BCNU maintenance therapy in this clinical situation were significantly greater than toxic effects associated with no maintenance therapy.
D001424:Bacterial Infections / Q000209:etiology; D001853:Bone Marrow / Q000187:drug effects; D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D012075:Remission, Spontaneous
D002330:Carmustine